People · Operator
Named in public records as an officer, director or promoter · active 2011–2014 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neos Therapeutics, Inc. | — | Pharmaceuticals | Series B | $163.6M | $701.3M | 2013 |
| VYNE Therapeutics Inc. | — | Pharmaceuticals | Series C | $139.5M | $971.1M | 2012 |
| BIND Biosciences Inc | — | Biotechnology | Series B | $51.4M | $345.2M | 2011 |
| Spitfire Pharma, Inc. | — | Pharmaceuticals | Pre-Seed | $500K | $23.7M | 2012 |
Edward Schnipper at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Edward Schnipper on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Perlman | 1 | 15 |
| Peter Barton Hutt | 1 | 14 |
| Robert S Langer | 1 | 14 |
| James Wright | 1 | 9 |
| Noubar Afeyan | 1 | 9 |
| Scott Minick | 1 | 7 |
| Daniel S. Lynch | 1 | 6 |
| John Clark | 1 | 5 |
| Bryant Fong | 1 | 5 |
| Andrea Franz | 1 | 4 |
| Omid Farokhzad | 1 | 4 |
| Victor Miller | 1 | 4 |
| Anthony Bruno | 1 | 4 |
| AMIR S. NASHAT | 1 | 3 |
| Amir H. Nashat | 1 | 3 |
| Karl Handelsman | 1 | 3 |
| BRETT CUMMINGS | 1 | 3 |
| Omid C. Farokhzad | 1 | 3 |
| Bryan Hill | 1 | 3 |
| Robert S. Langer, Jr. | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.